Lyell Immunopharma announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 for treating relapsed and/or refractory large B-cell lymphomaB-cell lymphoma in adults after two or more prior lines of therapy. LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy, aims to improve complete response rates and extend remission duration compared to existing CD19-targeted CAR T-cell therapies. This designation stems from promising early clinical data from an ongoing Phase 1/2 trial.
This RMAT designation is crucial for advancing the treatment landscape for aggressive large B-cell lymphoma. Current therapies often fall short in providing durable remissions, leaving a significant unmet need for patients who relapse or don’t respond to initial treatments. The dual-targeting approach of LYL314 and its enhanced manufacturing process, designed to enrich for more durable T-cells, holds the potential to overcome the limitations of current therapies and provide deeper, longer-lasting responses. This could translate into improved survival and quality of life for patients facing this aggressive cancer.
The RMAT designation grants Lyell benefits similar to Breakthrough Therapy and Fast Track designations, including increased interaction with the FDA and potential for expedited approval. Early clinical data from the Phase 1/2 trial showed a 94% overall response rate and a 71% complete response rate in patients with relapsed or refractory large B-cell lymphoma who had received at least three prior lines of therapy. Importantly, no Grade 3 or higher cytokine release syndrome, a serious side effect of CAR T-cell therapy, was observed. Further data from this trial, including results from patients in earlier lines of treatment, are expected later this year. Lyell also plans to initiate two pivotal trials for LYL314, one for patients in the third line or later setting in mid-2025 and another for second-line patients by early 2026.
This RMAT designation underscores the potential of LYL314 to become a leading treatment option for aggressive large B-cell lymphoma. The upcoming clinical data releases and planned pivotal trials will be critical milestones in confirming its efficacy and safety profile, potentially paving the way for regulatory approval and ultimately transforming the outlook for patients with this challenging cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
